News
🇪🇺 EuropeLatest pharmaceutical news, drug approvals, and EMA regulatory updates
Latest News
LENZ Therapeutics Submits VIZZ® Application to EMA for Presbyopia
LENZ Therapeutics has announced the submission of a marketing authorization application for VIZZ® to the European Medicines Agency for the treatment of presbyopia. This development could reshape the landscape for presbyopia treatments in Europe.
Innovent Biologics and Pfizer's $10.5 Billion Cancer Drug Deal
Innovent Biologics and Pfizer have entered a significant $10.5 billion deal for a cancer drug, marking a pivotal moment in China's biotech landscape. This article explores the implications for the pharmaceutical industry.
Innovent Biologics Shares Surge 10% Following Pfizer Deal
Innovent Biologics' shares have surged by 10% following a major partnership with Pfizer valued at up to $10.5 billion. This article analyzes the market impact and future implications.
Arrowhead Pharmaceuticals Unveils Positive Clinical Data at EAS Congress
Arrowhead Pharmaceuticals has presented promising clinical data on cardiometabolic disorders at the EAS Congress, signaling potential market opportunities.
ESMO 2025 Preview: Astra and Daiichi vs. Gilead
As ESMO 2025 approaches, Astra and Daiichi are positioning themselves against Gilead. This article analyzes the implications for investors and pharma teams.
Critical Medicines Act: Council and Parliament Reach Provisional Deal
The Council and Parliament have reached a provisional deal on the Critical Medicines Act, marking a significant development in pharmaceutical regulation. This article analyzes the market implications for BD teams, investors, and analysts.
Navigating the 2026 Cell Therapy Regulatory Landscape
This article provides an overview of the 2026 regulatory landscape for cell therapy, emphasizing the alignment of CMC strategies with FDA and EMA expectations.
IMFINZI® Approved for High-Risk Bladder Cancer: A Game Changer
AstraZeneca's IMFINZI® (durvalumab) has received FDA approval as the first immunotherapy combination for BCG-naïve, high-risk non-muscle-invasive bladder cancer, marking a significant advancement in oncology treatment options.
PRAC Meeting Highlights: Regulatory Updates from May 2026
The PRAC meeting from May 4-7, 2026, provided crucial regulatory updates impacting the pharmaceutical industry. Key takeaways highlight the implications for business development teams and investors.
Merz Therapeutics and Kvvit Enter Exclusive Agreement for INBRIJA®
Merz Therapeutics has entered an exclusive agreement with Kvvit for INBRIJA® (levodopa inhalation powder). This partnership marks a significant regulatory update in the pharmaceutical landscape.
Imfinzi Receives FDA Approval for Bladder Cancer Treatment
AstraZeneca's Imfinzi has been approved by the FDA for a new indication in bladder cancer treatment. This approval opens new avenues for investment and market competition.
Critical Medicines Act Targets Europe's Medicines Shortages
The Critical Medicines Act aims to address Europe's pressing medicine shortages. This article analyzes its market implications for pharmaceutical stakeholders.
Hansa Licenses Idefirix to SERB for $133M: Implications for Investors
Hansa Biopharma has licensed Idefirix to SERB for $133 million. This deal marks a significant milestone in the drug's clinical development and investment landscape.
EMA Management Board Meeting Highlights: March 2026 on Clinical Trials
The EMA Management Board's March 2026 meeting focused on critical updates regarding clinical trials. This article outlines key takeaways and their implications for the pharmaceutical sector.
Imfinzi Approved for Unique Bladder Cancer Combo: A Game Changer
AstraZeneca's Imfinzi has secured FDA approval for a novel bladder cancer combination therapy, marking a significant advancement in oncology treatment options. This approval is expected to reshape the competitive landscape and investment strategies in the pharmaceutical sector.
Tarsier Pharma IPO: NYSE Listings Expand with New Opportunities
Tarsier Pharma is set to launch its IPO on the NYSE, targeting a share price between $8 and $10. This move marks a significant expansion in the pharmaceutical sector.
Camizestrant Recommended for Approval in the EU for Advanced ER-Positive Breast Cancer
The CHMP has recommended the approval of Camizestrant in combination with a CDK4/6 inhibitor for first-line treatment of advanced ER-positive breast cancer in the EU. This decision could reshape treatment protocols and investment strategies in the oncology sector.
AI Accelerates Novo Nordisk's Parkinson’s Cell Therapy
Novo Nordisk is leveraging AI to enhance its Parkinson's cell therapy development. This advancement could reshape the market landscape for investors and analysts.
European Critical Medicines Act: Market Analysis and Implications
The European Critical Medicines Act is set to reshape the pharmaceutical landscape. This article analyzes its market implications for business development teams and investors.
EU Draft Deal Addresses Essential Medicine Shortages
The EU has reached a provisional agreement to tackle essential medicine shortages, a significant step for the pharmaceutical industry. This article analyzes the market implications for BD teams and investors.